<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/89F66D08-390A-4D3A-9C7C-6780F6F7A1AC"><gtr:id>89F66D08-390A-4D3A-9C7C-6780F6F7A1AC</gtr:id><gtr:name>University of Southern Denmark</gtr:name><gtr:address><gtr:line1>Campusvej 55</gtr:line1><gtr:line4>Odense M</gtr:line4><gtr:postCode>DK-5230</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/FAE32A25-51D3-49EF-998F-281B3A47C212"><gtr:id>FAE32A25-51D3-49EF-998F-281B3A47C212</gtr:id><gtr:name>Helmholtz Association of German Research Centres</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:department>Infection Immunity and Inflammation</gtr:department><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/89F66D08-390A-4D3A-9C7C-6780F6F7A1AC"><gtr:id>89F66D08-390A-4D3A-9C7C-6780F6F7A1AC</gtr:id><gtr:name>University of Southern Denmark</gtr:name><gtr:address><gtr:line1>Campusvej 55</gtr:line1><gtr:line4>Odense M</gtr:line4><gtr:postCode>DK-5230</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/FAE32A25-51D3-49EF-998F-281B3A47C212"><gtr:id>FAE32A25-51D3-49EF-998F-281B3A47C212</gtr:id><gtr:name>Helmholtz Association of German Research Centres</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/E3FF04F3-296B-4065-AC0D-AEC75CA301D9"><gtr:id>E3FF04F3-296B-4065-AC0D-AEC75CA301D9</gtr:id><gtr:firstName>Wilhelm</gtr:firstName><gtr:surname>Schwaeble</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/380C75EB-5798-45D1-8DF6-522F675834C8"><gtr:id>380C75EB-5798-45D1-8DF6-522F675834C8</gtr:id><gtr:firstName>Russell</gtr:firstName><gtr:surname>Wallis</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0501425"><gtr:id>230DD2F9-C6C1-44A2-9465-9CCA47FE0B05</gtr:id><gtr:title>Molecular recognition and regulation of the lectin pathway of complement activation</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0501425</gtr:grantReference><gtr:abstractText>The complement system is a fundamental part of the mammalian immune system, neutralising potentially harmful bacteria, viruses and parasites. A relatively poorly understood branch of this system, called the lectin pathway, relies on recognition of carbohydrates on the surfaces of invading microorganisms to initiate the complement cascade. The lectin pathway is particularly important in the early stages of infection, before specific antibodies can be synthesized by the host or when the immune system is suppressed, for example during HIV infection or following chemotherapy. It kills pathogens directly and also stimulates and directs other parts of the immune system to generate an appropriate response. Although the lectin pathway normally has a protective role, under certain conditions, it can cause severe damage to host tissues. For example, lectin pathway dependent complement activation is believed to cause substantial cardiovascular damage following restoration of blood flow following myocardial infarction. In this grant proposal, we aim to develop a better understanding of the lectin pathway of complement activation by studying the way in which the components interact with each other to initiate and regulate the reaction cascade. We have already established methods for producing key elements using recombinant DNA technology, so that their mode of action can be investigated in a systematic way. Using the results from these studies, we plan to develop specific inhibitors to lectin pathway activation. These inhibitors will be useful tools to help us understand the role of the lectin pathway in complex biological processes and will also serve as potential drugs for the treatment of diseases, including heart and kidney disease. An additional goal of this project is to change the properties of components of the lectin pathway so that they bind to carbohydrates that are present on the surfaces of tumour cells but are not normally found on healthy tissues. We will test the abilities of these modified components to stimulate the immune system to neutralize tumour cells. The knowledge provided by our research will be translated to the scientific community through publication in high quality scientific journals and by presentations at international conferences. Our research will be communicated to the general public through the University and Departmental Web pages via the University Press Office. In particular, important discoveries will be published in the bimonthly University newletter and in the Annual Report, which highlights major achievements of the University.</gtr:abstractText><gtr:technicalSummary>The goal of the proposed work is to understand how molecular interactions regulate the function of the lectin pathway of complement activation. The results of this study are expected to be of significance to both basic and therapeutic applications. Understanding the fundamental issues of recognition in complement activation has general practical applications in protein engineering and for the design of inhibitors of macromolecular interactions. Biochemical and structural approaches are specifically designed to identify detailed interaction and structural information for MBL-MASP and ficolin-MASP interactions. Based on these studies, short constrained peptide mimics of bioactive protein surfaces will be developed, synthesized and characterized. The peptide mimics will serve as specific inhibitors of lectin-MASP interactions, providing a novel set of reagents to dissect the complex pathways that these proteins mediate. In addition these compounds represent potential first generation therapeutic agents for complement-mediated host damage, including reperfusion damage to myocardium, kidney and other tissues. We also plan to use our knowledge of lectin-carbohydrate interactions to engineer novel lectin-specificities into the framework of MBL and ficolins, thereby altering target specificity whilst retaining the ability to activate complement and stimulate the host?s immune system. By targeting sugars commonly found on tumour cells but rarely associated with healthy cells, we aim to develop a range of immunologically active reagents that are selective for diseased tissues.</gtr:technicalSummary><gtr:fund><gtr:end>2010-12-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>357863</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Helmholtz Association of German Research Centres</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>The Max Delbr?ck Center for Molecular Medicine (MDC)</gtr:department><gtr:description>Role of MBL and C1q in brain function</gtr:description><gtr:id>B7F0A03C-6F96-4F12-90FA-C9BAAD0B5DD1</gtr:id><gtr:impact>18831010</gtr:impact><gtr:partnerContribution>Using our recombinant proteins to study microglial function</gtr:partnerContribution><gtr:piContribution>Supply purified rat C1q and purified recombinant MBL for studies on microglial cells</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Southern Denmark (Syddansk Universitet)</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:department>Medical Biotechnology Center Southern Denmark</gtr:department><gtr:description>Molecular characterization of a novel chitin receptor FIBCD-1</gtr:description><gtr:id>8E829E8C-6AB4-4BC6-86FA-18BB7B7AD202</gtr:id><gtr:impact>19892701</gtr:impact><gtr:partnerContribution>Identification and preliminary characterization of a novel ficolin-like receptor</gtr:partnerContribution><gtr:piContribution>CHaracterization of FIBCD-1 using biophysical methods (analytical ultracentrifugation)</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Warwick</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Warwick Medical School</gtr:department><gtr:description>Molecular interactions in the immune system</gtr:description><gtr:id>EDC10E7C-C871-4F3E-B640-9E8016F031AC</gtr:id><gtr:impact>18831010, 20932025, 20674073, 20118239</gtr:impact><gtr:partnerContribution>Molecular characterization using Proteon XPR36 system</gtr:partnerContribution><gtr:piContribution>Characterization of interactions of MBL with MASPs, ficolins with MASPs and C1q with C1r and C1s</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>School work experience</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>516837AE-DBA1-48D1-A0FD-C2D6C128327B</gtr:id><gtr:impact>We have hosted a number (6 in total; 2 per year) of work experience students from local schools and colleges for 1 or 2 week periods. During this time, we explained our research , showed the students how to work safely in the laboratory and helped them to contribute towards our research e.g. through setting up PCR reactions, running gels and assisting in basic laboratory work. In one case, a student was keen to return to the lab to work during the summer holidays (between the lower and upper 6th form). In recognition of his contribution, the student will be a named author in an MRC-funded manuscript which will be submitted for publication in the coming year.

Work contributed by one of the students will be sumitted for publication in 2010.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>438792</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC project grant</gtr:description><gtr:end>2013-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>1EC5426F-AC53-45A4-B88C-D756F755A9BB</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Equipment grant</gtr:description><gtr:end>2010-06-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>4579B61C-D386-40AA-8CCC-9C14BD38A205</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>55000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>VIP Fellowship</gtr:description><gtr:end>2009-09-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>EB9B0B6F-7FB4-4E7C-831D-71ABC51E5B3A</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>600000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant</gtr:description><gtr:end>2012-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>7AF7F04B-7ADB-4EC4-93BC-BBEF58B6EAEF</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>532558</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC project grant</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/K011715/1</gtr:fundingRef><gtr:id>C62D319B-1567-4AF2-BC18-A69CAD377AE5</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Target for MBL-MASP inhibition by small molecule inhibitors</gtr:description><gtr:id>BA3522D6-AB8B-4E0C-9FAB-CAC328EEFFDE</gtr:id><gtr:impact>Work in progess</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>US2012225437</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Inhibition of MASP using small molecule inhibitors</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have recently generated a recombinant form of human C1q, the first component of the classical pathway of complement, by co-expressing the three polypeptide chains, from which it is assembled, in a Chinese hamster ovary cell line. This has not been achieved before despite considerable efforts by us (as well as other research groups throughout the world), and is a major breakthrough. It will enable detailed study of the many important physiological roles of C1q within maintenance of human and animal health and will also facilitate understanding of the contribution of C1q to disease progression, e.g. the role of C1q in inflammatory diseases such as rheumatoid arthritis and lupus erythmatosus.</gtr:description><gtr:id>5B1E0379-7440-4072-93CF-A74A0188A141</gtr:id><gtr:impact>The reagent was only developed recently (within the last six months), so there has not been sufficient time to exploit its benefits fully. However, we confidently predict that it will become a widely used resourse, both by us and other researchers worldwide, to study the role of C1q in health and disease, using in vitro and in vivo approaches.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Recombinant C1q</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BE36B2AE-C1E6-471B-804E-DBCF0B6DC585"><gtr:id>BE36B2AE-C1E6-471B-804E-DBCF0B6DC585</gtr:id><gtr:title>Opsonizing properties of rat ficolin-A in the defence against Cryptococcus neoformans.</gtr:title><gtr:parentPublicationTitle>Immunobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f2ad1c5550012bc220f27087901807ba"><gtr:id>f2ad1c5550012bc220f27087901807ba</gtr:id><gtr:otherNames>Schelenz S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0171-2985</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/467012E0-B64E-4CF0-B9E4-CFC86DEB35AC"><gtr:id>467012E0-B64E-4CF0-B9E4-CFC86DEB35AC</gtr:id><gtr:title>Localization and characterization of the mannose-binding lectin (MBL)-associated-serine protease-2 binding site in rat ficolin-A: equivalent binding sites within the collagenous domains of MBLs and ficolins.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/91b76022d1735bd30d4037f8a0d484e4"><gtr:id>91b76022d1735bd30d4037f8a0d484e4</gtr:id><gtr:otherNames>Girija UV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C3D1A8C8-29B4-4EF1-B580-E83576687A63"><gtr:id>C3D1A8C8-29B4-4EF1-B580-E83576687A63</gtr:id><gtr:title>Analogous interactions in initiating complexes of the classical and lectin pathways of complement.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0831d18646fcf043f07d08613614d185"><gtr:id>0831d18646fcf043f07d08613614d185</gtr:id><gtr:otherNames>Phillips AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/96D7B122-1648-4749-992F-A1CCC0AB7E77"><gtr:id>96D7B122-1648-4749-992F-A1CCC0AB7E77</gtr:id><gtr:title>Molecular basis of sugar recognition by collectin-K1 and the effects of mutations associated with 3MC syndrome.</gtr:title><gtr:parentPublicationTitle>BMC biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/81e05113304b82f1e64e218eba6b287b"><gtr:id>81e05113304b82f1e64e218eba6b287b</gtr:id><gtr:otherNames>Venkatraman Girija U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1741-7007</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/45BAC4A5-6E9F-44DD-B833-EFAFF7BF170D"><gtr:id>45BAC4A5-6E9F-44DD-B833-EFAFF7BF170D</gtr:id><gtr:title>Near-planar solution structures of mannose-binding lectin oligomers provide insight on activation of lectin pathway of complement.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/85627c6740fc4161499910b00f7a76e7"><gtr:id>85627c6740fc4161499910b00f7a76e7</gtr:id><gtr:otherNames>Miller A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/40FE055F-60A9-49EA-9FEA-29C3D092C086"><gtr:id>40FE055F-60A9-49EA-9FEA-29C3D092C086</gtr:id><gtr:title>High-affinity glycopolymer binding to human DC-SIGN and disruption of DC-SIGN interactions with HIV envelope glycoprotein.</gtr:title><gtr:parentPublicationTitle>Journal of the American Chemical Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/df1860b498428d9394b26bbdae696daa"><gtr:id>df1860b498428d9394b26bbdae696daa</gtr:id><gtr:otherNames>Becer CR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0002-7863</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/67F5892C-5BA2-44A2-8D39-118F017FE849"><gtr:id>67F5892C-5BA2-44A2-8D39-118F017FE849</gtr:id><gtr:title>Interactions between mannose-binding lectin and MASPs during complement activation by the lectin pathway.</gtr:title><gtr:parentPublicationTitle>Immunobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f62e9dbdf9d563e4f455a8133df400e5"><gtr:id>f62e9dbdf9d563e4f455a8133df400e5</gtr:id><gtr:otherNames>Wallis R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0171-2985</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B152342D-A38B-4076-81B1-1548F37059D0"><gtr:id>B152342D-A38B-4076-81B1-1548F37059D0</gtr:id><gtr:title>Structural basis of mannan-binding lectin recognition by its associated serine protease MASP-1: implications for complement activation.</gtr:title><gtr:parentPublicationTitle>Structure (London, England : 1993)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1c66d2c715a27dc0d663cbd094376b44"><gtr:id>1c66d2c715a27dc0d663cbd094376b44</gtr:id><gtr:otherNames>Gingras AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0969-2126</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/70BFBD72-D109-423D-9C0C-C561AB08C751"><gtr:id>70BFBD72-D109-423D-9C0C-C561AB08C751</gtr:id><gtr:title>High glucose disrupts oligosaccharide recognition function via competitive inhibition: a potential mechanism for immune dysregulation in diabetes mellitus.</gtr:title><gtr:parentPublicationTitle>Immunobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/66de6dc8e5e7bc9524bdda5739f72175"><gtr:id>66de6dc8e5e7bc9524bdda5739f72175</gtr:id><gtr:otherNames>Ilyas R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0171-2985</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8CB0637C-2711-4486-8104-453CB074A7C8"><gtr:id>8CB0637C-2711-4486-8104-453CB074A7C8</gtr:id><gtr:title>Simultaneous activation of complement and coagulation by MBL-associated serine protease 2.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/23309d9bb5ff49f940a308630674622c"><gtr:id>23309d9bb5ff49f940a308630674622c</gtr:id><gtr:otherNames>Krarup A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/10C7167A-8871-42D9-A709-30A84759D19C"><gtr:id>10C7167A-8871-42D9-A709-30A84759D19C</gtr:id><gtr:title>The recognition unit of FIBCD1 organizes into a noncovalently linked tetrameric structure and uses a hydrophobic funnel (S1) for acetyl group recognition.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/08c34e71c31bc525a320d33a2718dc95"><gtr:id>08c34e71c31bc525a320d33a2718dc95</gtr:id><gtr:otherNames>Thomsen T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/59A5436B-30D2-4B15-A539-E69FDDD99E7B"><gtr:id>59A5436B-30D2-4B15-A539-E69FDDD99E7B</gtr:id><gtr:title>Carbohydrate recognition and complement activation by rat ficolin-B.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/91b76022d1735bd30d4037f8a0d484e4"><gtr:id>91b76022d1735bd30d4037f8a0d484e4</gtr:id><gtr:otherNames>Girija UV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CEAD41D0-6909-4982-9985-89697100BD7E"><gtr:id>CEAD41D0-6909-4982-9985-89697100BD7E</gtr:id><gtr:title>Engineering novel complement activity into a pulmonary surfactant protein.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/81e05113304b82f1e64e218eba6b287b"><gtr:id>81e05113304b82f1e64e218eba6b287b</gtr:id><gtr:otherNames>Venkatraman Girija U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0409E6CA-FE9B-4B4E-9C64-F7406D5CDF2D"><gtr:id>0409E6CA-FE9B-4B4E-9C64-F7406D5CDF2D</gtr:id><gtr:title>Paths reunited: Initiation of the classical and lectin pathways of complement activation.</gtr:title><gtr:parentPublicationTitle>Immunobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f62e9dbdf9d563e4f455a8133df400e5"><gtr:id>f62e9dbdf9d563e4f455a8133df400e5</gtr:id><gtr:otherNames>Wallis R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0171-2985</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DFEFB010-7F0A-41CC-A648-5AB7EF7414D7"><gtr:id>DFEFB010-7F0A-41CC-A648-5AB7EF7414D7</gtr:id><gtr:title>C1q, the recognition subcomponent of the classical pathway of complement, drives microglial activation.</gtr:title><gtr:parentPublicationTitle>Journal of neuroscience research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b77cfd0e65030d2a4d300804fff054a3"><gtr:id>b77cfd0e65030d2a4d300804fff054a3</gtr:id><gtr:otherNames>F?rber K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0360-4012</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0501425</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>